CD40LG and metabolic dysfunction-associated steatohepatitis: Although most of the above-mentioned immunization approaches have been reported to be successful for atherosclerosis, more studies focusing on liver disease are required to further confirm that the treatment principles of increased anti-OSE IgM to reduce atherosclerosis also apply to NASH.